For Regeneron, Near-Term PCSK9 Filing, Eylea Growth Point To Rapidly Improving Prospects
This article was originally published in The Pink Sheet Daily
Executive Summary
Regeneron and partner Sanofi estimate there are more than 60 million addressable patients for LDL-lowering therapy in the U.S. and EU, including 22 million at very-high risk for a cardiovascular event. Meanwhile, a label addition for diabetic macular edema heightens the sales-growth prospects for Eylea.
You may also be interested in...
Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher
Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.
Preparing For Battle: PCSK9 Sponsors Stake Their Ground
The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.